HALO
Price
$39.98
Change
+$0.30 (+0.76%)
Updated
Nov 29, 10:24 AM EST
83 days until earnings call
MDGL
Price
$195.97
Change
+$5.03 (+2.63%)
Updated
Nov 29, 10:26 AM EST
85 days until earnings call
Ad is loading...

Compare trend and price HALO vs MDGL

Header iconHALO vs MDGL Comparison
Open Charts HALO vs MDGLBanner chart's image
Halozyme Therapeutics
Price$39.98
Change+$0.30 (+0.76%)
Volume$500
CapitalizationN/A
Madrigal Pharmaceuticals
Price$195.97
Change+$5.03 (+2.63%)
Volume$1.36K
CapitalizationN/A
View a ticker or compare two or three
HALO vs MDGL Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
HALO vs. MDGL commentary
Nov 29, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Hold and MDGL is a Buy.

COMPARISON
Comparison
Nov 29, 2023
Stock price -- (HALO: $39.68 vs. MDGL: $190.94)
Brand notoriety: HALO and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 111% vs. MDGL: 51%
Market capitalization -- HALO: $5.4B vs. MDGL: $3.9B
HALO [@Biotechnology] is valued at $5.4B. MDGL’s [@Biotechnology] market capitalization is $3.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 2 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 2 green, 3 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 7 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • HALO’s TA Score: 7 bullish, 3 bearish.
  • MDGL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, HALO is a better buy in the short-term than MDGL.

Price Growth

HALO (@Biotechnology) experienced а +2.06% price change this week, while MDGL (@Biotechnology) price change was +1.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +38.10%, and the average quarterly price growth was +9.12%.

Reported Earning Dates

HALO is expected to report earnings on Feb 20, 2024.

MDGL is expected to report earnings on Feb 22, 2024.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for HALO with price predictions.
OPEN
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
HALO($5.4B) has a higher market cap than MDGL($3.9B). HALO YTD gains are higher at: -30.264 vs. MDGL (-34.215). HALO has higher annual earnings (EBITDA): 407M vs. MDGL (-336.4M). HALO has more cash in the bank: 483M vs. MDGL (232M). MDGL has less debt than HALO: MDGL (117M) vs HALO (1.5B). HALO has higher revenues than MDGL: HALO (781M) vs MDGL (0).
HALOMDGLHALO / MDGL
Capitalization5.4B3.9B139%
EBITDA407M-336.4M-121%
Gain YTD-30.264-34.21588%
P/E Ratio21.83N/A-
Revenue781M0-
Total Cash483M232M208%
Total Debt1.5B117M1,280%
FUNDAMENTALS RATINGS
HALO vs MDGL: Fundamental Ratings
HALO
MDGL
OUTLOOK RATING
1..100
1828
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
31100
SMR RATING
1..100
12100
PRICE GROWTH RATING
1..100
4735
P/E GROWTH RATING
1..100
88100
SEASONALITY SCORE
1..100
3550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HALO's Valuation (83) in the Biotechnology industry is in the same range as MDGL (96) in the Pharmaceuticals Other industry. This means that HALO’s stock grew similarly to MDGL’s over the last 12 months.

HALO's Profit vs Risk Rating (31) in the Biotechnology industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that HALO’s stock grew significantly faster than MDGL’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that HALO’s stock grew significantly faster than MDGL’s over the last 12 months.

MDGL's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as HALO (47) in the Biotechnology industry. This means that MDGL’s stock grew similarly to HALO’s over the last 12 months.

HALO's P/E Growth Rating (88) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that HALO’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOMDGL
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 21 days ago
69%
Bearish Trend 21 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EWZ34.120.37
+1.10%
iShares MSCI Brazil ETF
SXUS16.630.04
+0.26%
Janus Henderson International Sus Eq ETF
HYGH83.90-0.11
-0.13%
iShares Interest Rate Hdg Hi Yld Bd ETF
IHE173.98-0.64
-0.37%
iShares US Pharmaceuticals ETF
SRS17.66-0.19
-1.06%
ProShares UltraShort Real Estate